ARPA-H defines its model for faster health breakthroughs

ARPA-H is positioning its funding model around high-impact healthcare problems that require approaches beyond traditional government or industry support. The agency says it seeks revolutionary advances that can produce health breakthroughs in years, not decades, with an emphasis on technologies that address broad problems and can apply across settings or indications.

The agency will not back incremental advances, work already at the clinical trial stage, or projects limited to education or physical infrastructure. Unlike NIH and NSF, ARPA-H says it does not invest in foundational or basic research, instead focusing on disease-agnostic platform capabilities that can translate bleeding-edge innovations into real-world results. Its cross-cutting priorities include chronic diseases, aging, domestic biomanufacturing, rural healthcare access and AI for healthcare.

ARPA-H describes its approach as active risk management across investment, regulation and adoption. It aims to prove concepts that other funders may avoid, work closely with the FDA on regulatory standards, and engage payers to improve the chances that doctors and patients adopt new tools. Program Managers monitor projects through regular assessments, continue the strongest work and coordinate teams across medical, academic and biotech sectors with a focus on outcomes measured in lives saved.